Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
223.2 USD | -1.41% | -1.92% | -11.27% |
Mar. 28 | Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate | MT |
Mar. 22 | Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.27% | 8.64B | |
+70.88% | 12.18B | |
+25.29% | 7.77B | |
-3.97% | 5.49B | |
-8.16% | 4.74B | |
-1.45% | 4.67B | |
+8.48% | 3.88B | |
-26.09% | 2.78B | |
+5.32% | 2.12B | |
+0.26% | 1.8B |
- Stock
- Equities
- Stock Penumbra, Inc. - Nyse
- News Penumbra, Inc.
- Wells Fargo Adjusts Penumbra's Price Target to $265 from $321, Keeps Overweight Rating